tetano
Editor, Senior Moderator
Nat Rev Drug Discov. 2020 Feb 14. doi: 10.1038/s41573-019-0056-x. [Epub ahead of print] [h=1]Next-generation influenza vaccines: opportunities and challenges.[/h]
Wei CJ[SUP]1[/SUP], Crank MC[SUP]2[/SUP], Shiver J[SUP]3[/SUP], Graham BS[SUP]2[/SUP], Mascola JR[SUP]2[/SUP], Nabel GJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Seasonal influenza vaccines lack efficacy against drifted or pandemic influenza strains. Developing improved vaccines that elicit broader immunity remains a public health priority. Immune responses to current vaccines focus on the haemagglutinin head domain, whereas next-generation vaccines target less variable virus structures, including the haemagglutinin stem. Strategies employed to improve vaccine efficacy involve using structure-based design and nanoparticle display to optimize the antigenicity and immunogenicity of target antigens; increasing the antigen dose; using novel adjuvants; stimulating cellular immunity; and targeting other viral proteins, including neuraminidase, matrix protein 2 or nucleoprotein. Improved understanding of influenza antigen structure and immunobiology is advancing novel vaccine candidates into human trials.
PMID: 32060419 DOI: 10.1038/s41573-019-0056-x
Wei CJ[SUP]1[/SUP], Crank MC[SUP]2[/SUP], Shiver J[SUP]3[/SUP], Graham BS[SUP]2[/SUP], Mascola JR[SUP]2[/SUP], Nabel GJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Seasonal influenza vaccines lack efficacy against drifted or pandemic influenza strains. Developing improved vaccines that elicit broader immunity remains a public health priority. Immune responses to current vaccines focus on the haemagglutinin head domain, whereas next-generation vaccines target less variable virus structures, including the haemagglutinin stem. Strategies employed to improve vaccine efficacy involve using structure-based design and nanoparticle display to optimize the antigenicity and immunogenicity of target antigens; increasing the antigen dose; using novel adjuvants; stimulating cellular immunity; and targeting other viral proteins, including neuraminidase, matrix protein 2 or nucleoprotein. Improved understanding of influenza antigen structure and immunobiology is advancing novel vaccine candidates into human trials.
PMID: 32060419 DOI: 10.1038/s41573-019-0056-x